EBS
Emergent BioSolutions Inc.NYSEHealthcare$8.23-1.79%ClosedMarket Cap: $426.1M
As of 2026-04-06
Valuation
P/E (TTM)
8.10
PEG
0.06
P/B
0.83
P/S
0.56
EV/EBITDA
3.90
DCF Value
$2.73
FCF Yield
37.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.2%
Operating Margin
14.8%
Net Margin
7.1%
ROE
9.6%
ROA
4.0%
ROIC
5.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $148.7M | 20.9% | $-17.8M | $-54.6M | $-0.95 | — |
| FY 2025 | $742.9M | 47.2% | $110.2M | $52.6M | $0.93 | — |
| Q3 2025 | $231.1M | 60.3% | $76.5M | $51.2M | $0.91 | — |
| Q2 2025 | $140.9M | 43.1% | $1.6M | $-12.0M | $-0.22 | — |
| Q1 2025 | $222.2M | 53.7% | $49.9M | $68.0M | $1.19 | — |
| Q4 2024 | $194.7M | 70.1% | $-9.5M | $-31.3M | $-0.59 | — |
| FY 2024 | $1.04B | 36.0% | $-108.7M | $-190.6M | $-3.60 | — |
| Q3 2024 | $293.8M | 55.9% | $64.5M | $114.8M | $2.06 | — |
| Q2 2024 | $254.7M | -25.7% | $-203.5M | $-283.1M | $-5.38 | — |
| Q1 2024 | $300.4M | 46.9% | $39.8M | $9.0M | $0.17 | — |
| Q4 2023 | $276.6M | 61.2% | $-43.8M | $-49.5M | $-0.95 | — |
| FY 2023 | $1.05B | 34.3% | $-726.4M | $-760.5M | $-14.85 | — |